4.3 Article

Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events A GENIUS-CHD Study of Individual Participant Data

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCGEN.119.002471

Keywords

chromosome; genetic; variation; myocardial infarction; risk factor; secondary prevention

Funding

  1. British Heart Foundation Intermediate Fellowship [FS/14/76/30933]
  2. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  3. UK Medical Research Council
  4. British Heart Foundation Intermediate Clinical Research Fellowship [FS/18/23/33512]
  5. National Institute for Health Research Oxford Biomedical Research Centre
  6. Netherlands Heart Foundation [2001D019, 2003T302, 2007B202, CVON 2012-10]
  7. Leducq Foundation [05-CVD]
  8. Center for Translational Molecular Medicine
  9. NIH (National Institutes of Health) [R0133169, R01ES021801, R01MD010358, R01ES025786, R01HL103866, R01DK106000, R01HL126827, P20HL113452, P01HL098055, P01HL076491, R01HL103931]
  10. NIHR
  11. Barts Charity
  12. Aarno Koskelo Foundation
  13. Helsinki University Central Hospital special government funds [TYH7215, TKK2012005, TYH2012209, TYH2014312]
  14. Finnish Foundation for Cardiovascular research
  15. National Heart Long and Blood Institute [A. Fox/R01 HL 098601]
  16. Heart Foundation of New Zealand
  17. National Institutes of Health/National Institutes of Aging [AG051633]
  18. Abraham J. AMP
  19. Phyllis Katz Foundation (Atlanta, GA)
  20. NIH [5P01HL101398-02, 1P20HL113451-01, 1R56HL126558-01, 1RF-1AG051633-01, R01 NS064162-01, R01 HL89650-01, HL095479-01, 1U10HL110302-01, 1DP3DK094346-01, 2P01HL086773-06A1]
  21. EU [692145]
  22. Estonian Research Council [IUT20-60, IUT24-6, PUT1660, PUT735]
  23. European Union [01KL1802, 2014-2020.4.01.15-0012]
  24. ERA-CVD grant Detectin-Heart failure [2R01DK075787-06A1]
  25. Canadian Institutes of Health Research
  26. Nova Scotia, Ontario
  27. Quebec (HSFC)
  28. Wellcome Trust [072960/Z/03/Z, 084726/Z/08/Z, 084727/Z/08/Z, 085475/Z/08/Z, 085475/B/08/Z]
  29. EU IMI-SUMMIT programme
  30. NHS Education of Scotland/Chief Scientist Office Postdoctoral Clinical Lectureship [PCL 17/07]
  31. Italian Ministry of Research's Fund for Basic Research
  32. Sanofi Aventis
  33. Chief Scientist Office, Scotland
  34. National Institute of Health Pharmacogenomics Research Network grant [U01-GM074492, R01 HL074730]
  35. University of Florida Opportunity Fund
  36. BASF Pharma
  37. German Ministry of Education and Research [01GD9820/0, 01ER0814]
  38. Willy-Robert-Pitzer Foundation
  39. Waldburg-Zeil Clinics Isny
  40. Polish Ministry of Science and Higher Education [NN402083939]
  41. National Science Centre [2013/09/B/NZ5/00770]
  42. Leipzig Research Center for Civilization Diseases (LIFE)
  43. European Union
  44. European Regional Development Fund (ERDF)
  45. Free State of Saxony
  46. Seventh Framework Program [201668]
  47. European Research Council Advanced Grant [294609]
  48. Italian Ministry of Health [PE-2013-02356818]
  49. Italian Ministry of Education, University and Research [2015583WMX]
  50. University of Ottawa Heart Institute
  51. Heart and Stroke Foundation
  52. Established Clinical Investigator of the Netherlands Heart Foundation [2001 D 032]
  53. European commission [223004]
  54. Netherlands Genomics Initiative (Netherlands Consortium for Healthy Aging) [050-060-810]
  55. FRSQ
  56. Merck Frost Canada
  57. Pfizer Canada
  58. Swedish Council for Work Life and Social Research
  59. Stockholm County Council
  60. Genome Canada
  61. Genome Quebec
  62. Canadian Institutes of Health Research (CIHR)
  63. Fonds de recherche du Quebec-Sante (FRQS)
  64. National Institutes of Health [Cresci R01 NR013396]
  65. National Institutes of Health: Washington University School of Medicine SCCOR [P50 HL077113]
  66. Dutch Top Institute Pharma Mondriaan Project
  67. Cariverona Foundation
  68. Veneto Region
  69. Italian Ministry of Education, University, and Research (MIUR)
  70. LURM (Laboratorio Universitario di Ricerca Medica) Research Center, University of Verona
  71. National Centre for Research and Development (NCBiR) [N R13 0001 06]
  72. Medical University of Warsaw
  73. British Heart Foundation
  74. University College London Hospitals NIHR Biomedical Research Centre
  75. EU/EF-PIA Innovative Medicines Initiative 2 Joint Undertaking BigData@Heart grant [116074]
  76. European Union's Horizon 2020 research and innovation programme under the ERA-NET Co-fund action [01KL1802]
  77. BHF [PG/18/5033837]
  78. Health Research Council
  79. Heart and Stroke Foundation of Alberta, NWT AMP
  80. Nunavut, British Columbia and Yukon
  81. Heart and Stroke Foundation of NWT Nunavut
  82. Heart and Stroke Foundation of British Columbia
  83. Heart and Stroke Foundation of Yukon
  84. Institute of Clinical and Experimental Medicine, Prague [00023001]
  85. Wellcome Trust
  86. Abbott Laboratories
  87. Epidemiologia e Genetica della Morte Improvvisa in Sardegna
  88. National Science Center (Poland) [N N 402 529139]
  89. Bristol Myers Squibb USA
  90. HSFC
  91. Pfizer
  92. Netherlands Heart Foundation
  93. European Research Council (ERC) [294609] Funding Source: European Research Council (ERC)

Ask authors/readers for more resources

BACKGROUND: Genetic variation at chromosome 9p21 is a recognized risk factor for coronary heart disease (CHD). However, its effect on disease progression and subsequent events is unclear, raising questions about its value for stratification of residual risk. METHODS: A variant at chromosome 9p21 (rs1333049) was tested for association with subsequent events during follow-up in 103 357 Europeans with established CHD at baseline from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) Consortium (73.1% male, mean age 62.9 years). The primary outcome, subsequent CHD death or myocardial infarction (CHD death/myocardial infarction), occurred in 13 040 of the 93 115 participants with available outcome data. Effect estimates were compared with case/control risk obtained from the CARDIoGRAMplusC4D consortium (Coronary Artery Disease Genome-wide Replication and Meta-analysis [CARDIoGRAM] plus The Coronary Artery Disease [C4D] Genetics) including 47 222 CHD cases and 122 264 controls free of CHD. RESULTS: Meta-analyses revealed no significant association between chromosome 9p21 and the primary outcome of CHD death/myocardial infarction among those with established CHD at baseline (GENIUSCHD odds ratio, 1.02; 95% CI, 0.99-1.05). This contrasted with a strong association in CARDIoGRAMPlusC4D odds ratio 1.20; 95% CI, 1.18-1.22; P for interaction < 0.001 compared with the GENIUS-CHD estimate. Similarly, no clear associations were identified for additional subsequent outcomes, including all-cause death, although we found a modest positive association between chromosome 9p21 and subsequent revascularization (odds ratio, 1.07; 95% CI, 1.04-1.09). CONCLUSIONS: In contrast to studies comparing individuals with CHD to disease-free controls, we found no clear association between genetic variation at chromosome 9p21 and risk of subsequent acute CHD events when all individuals had CHD at baseline. However, the association with subsequent revascularization may support the postulated mechanism of chromosome 9p21 for promoting atheroma development.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available